| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018003782 |
| P356 | DOI | 10.1186/S13073-016-0362-4 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s13073-016-0362-4 |
| P932 | PMC publication ID | 5075982 |
| P698 | PubMed publication ID | 27776531 |
| P50 | author | Yann Joly | Q46004599 |
| Jian Carrot-Zhang | Q47460811 | ||
| P2093 | author name string | Jian Carrot-Zhang | |
| Gabrielle Bertier | |||
| Vassilis Ragoussis | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Medical implications of technical accuracy in genome sequencing | Q23005220 | ||
| Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours | Q24234616 | ||
| Global implementation of genomic medicine: We are not alone | Q24658586 | ||
| Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer | Q26746010 | ||
| The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis | Q26765401 | ||
| Socioeconomic position in childhood and cancer in adulthood: a rapid-review | Q26771659 | ||
| Universes collide: combining immunotherapy with targeted therapy for cancer | Q26825316 | ||
| The genetic basis for cancer treatment decisions | Q26849200 | ||
| Genomics, personalized medicine, and supportive cancer care | Q26863765 | ||
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine | Q27853005 | ||
| Trends in guideline implementation: a scoping systematic review | Q28084735 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium | Q28601251 | ||
| Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects | Q28610872 | ||
| Why don't physicians follow clinical practice guidelines? A framework for improvement | Q29619967 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data | Q30387579 | ||
| An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. | Q30581758 | ||
| Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers | Q30674708 | ||
| Is Whole-Exome Sequencing an Ethically Disruptive Technology? Perspectives of Pediatric Oncologists and Parents of Pediatric Patients With Solid Tumors | Q30798291 | ||
| The translation of cancer genomics: time for a revolution in clinical cancer care | Q33772611 | ||
| Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis | Q33845209 | ||
| ACMG clinical laboratory standards for next-generation sequencing | Q33903280 | ||
| Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality | Q34135443 | ||
| Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges | Q34185078 | ||
| Expanding the computational toolbox for mining cancer genomes | Q34207474 | ||
| Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics | Q34501849 | ||
| Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. | Q34529131 | ||
| Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer | Q34736112 | ||
| Population genetic testing for cancer susceptibility: founder mutations to genomes | Q38611712 | ||
| Next-generation sequencing and empowering personalised cancer medicine | Q38614403 | ||
| Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. | Q38651951 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Liquid Biopsies in Oncology and the Current Regulatory Landscape | Q38871132 | ||
| A Genetic Lung Cancer Susceptibility Test may have a Positive Effect on Smoking Cessation | Q39097035 | ||
| Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States | Q39734134 | ||
| The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections | Q40756146 | ||
| Seven Questions for Personalized Medicine | Q40812259 | ||
| Do we understand the personalized medicine paradigm? Personalized medicine marks the beginning of a new attitude in medicine. | Q42104770 | ||
| Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. | Q44523764 | ||
| Good laboratory practice for clinical next-generation sequencing informatics pipelines. | Q46420039 | ||
| Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. | Q52996551 | ||
| Understanding 'anticipatory governance'. | Q53522547 | ||
| The effect of genetic test-based risk information on behavioral outcomes: A critical examination of failed trials and a call to action. | Q53575353 | ||
| AstraZeneca launches project to sequence 2 million genomes. | Q54541236 | ||
| Fifteen important questions for oncology to be addressed from 2015 | Q57570540 | ||
| Statement of principles on the return of research results and incidental findings in paediatric research: a multi-site consultative process | Q57641728 | ||
| ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing | Q57642222 | ||
| Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare | Q60716860 | ||
| Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment | Q85774777 | ||
| [Personalized medicine: equity and access] | Q86016843 | ||
| ??? | Q28075000 | ||
| Next-generation sequencing in clinical oncology: next steps towards clinical validation | Q34774908 | ||
| Analytical validation of whole exome and whole genome sequencing for clinical applications | Q35155705 | ||
| Concepts of 'personalization' in personalized medicine: implications for economic evaluation. | Q35575935 | ||
| Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival | Q35809413 | ||
| Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets | Q35869744 | ||
| Gene-panel sequencing and the prediction of breast-cancer risk | Q36175072 | ||
| A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. | Q36379244 | ||
| Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials | Q36534696 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Guidelines for diagnostic next-generation sequencing | Q36695835 | ||
| Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine | Q36698414 | ||
| Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers | Q36706659 | ||
| Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project | Q36724985 | ||
| Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers | Q36851421 | ||
| Genomic Information may Inhibit Weight-Related Behavior Change Inclinations Among Individuals in a Fear State | Q36902119 | ||
| BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. | Q36902674 | ||
| Harm, hype and evidence: ELSI research and policy guidance | Q36998724 | ||
| Personalized genomic disease risk of volunteers | Q37240475 | ||
| Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine | Q37508612 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| Genomic medicine frontier in human solid tumors: prospects and challenges | Q38099305 | ||
| Implementing personalized cancer genomics in clinical trials | Q38102920 | ||
| Genomic medicine: a decade of successes, challenges, and opportunities | Q38114005 | ||
| Rare-disease genetics in the era of next-generation sequencing: discovery to translation | Q38133704 | ||
| The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? | Q38151562 | ||
| Molecularly targeted cancer therapy: some lessons from the past decade | Q38173136 | ||
| Is individualized medicine more cost-effective? A systematic review | Q38191496 | ||
| Genetic diagnosis of autism spectrum disorders: the opportunity and challenge in the genomics era. | Q38216145 | ||
| Therapeutic vaccines for cancer: an overview of clinical trials | Q38227030 | ||
| Ethics and genomic medicine, how to navigate decisions in surgical oncology | Q38245663 | ||
| Hurdles on the road to personalized medicine | Q38250141 | ||
| Building the foundation for genomics in precision medicine | Q38385958 | ||
| Immune biomarkers: the promises and pitfalls of personalized medicine. | Q38392912 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 108 | |
| P577 | publication date | 2016-10-24 | |
| P1433 | published in | Genome Medicine | Q15816848 |
| P1476 | title | Integrating precision cancer medicine into healthcare-policy, practice, and research challenges | |
| P478 | volume | 8 |
| Q92807912 | A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine |
| Q53128895 | Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. |
| Q57173056 | Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold? |
| Q47606195 | Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer. |
| Q92570561 | Counting Oceanians of Non-European, Non-Asian Descent (ONENA) in the South Pacific to Make Them Count in Global Health |
| Q91570307 | DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study |
| Q59127501 | Sharing longitudinal, non-biological birth cohort data: a cross-sectional analysis of parent consent preferences |
| Q38993286 | Unsolved challenges in pediatric whole-exome sequencing: A literature analysis |
Search more.